ORGO vs RCEL
ORGO: A regenerative medicine company providing advanced wound care and surgical tissue-engineered products to improve healing outcomes in patients with chronic and acute wounds. RCEL: AVITA Medical provides regenerative, point-of-care cell harvesting technology and wound management solutions to transform acute wound care.
Side-by-side fundamentals
| Metric | ORGO | RCEL | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $1.02 | $13.80 | |
| Market cap | $131M | $427M | |
| Net margin FY2025, SEC XBRL | +6.6% | -67.8% | ORGO higher |
| Gross margin | +76.0% | +82.1% | RCEL higher |
| Operating margin FY2025, SEC XBRL | +7.9% | -59.4% | ORGO higher |
| ROE FY2025, SEC XBRL | +12.3% | n/a | |
| ROA FY2025, SEC XBRL | +6.2% | -86.2% | ORGO higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +17.0% | +11.4% | ORGO higher |
| Revenue CAGR (3y) SEC XBRL | +7.8% | +27.7% | RCEL higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.55 | 1.36 | |
| 1-year return as of 2026-10-20 close | -75.0% | +244.1% | RCEL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.